Cargando…

Local and Systemic Immunity During Five Vaccinations Against SARS-CoV-2 in Zanubrutinib-Treated Patients With Chronic Lymphocytic Leukemia

BACKGROUND: Patients with chronic lymphocytic leukemia (CLL) are vulnerable to coronavirus disease 2019 (COVID-19) and are at risk of inferior response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination, especially if treated with the first-generation Bruton’s tyrosine kinas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andersson, Maria, Wu, Jinghua, Wullimann, David, Gao, Yu, Aberg, Mikael, Muschiol, Sandra, Healy, Katie, Naud, Sabrina, Bogdanovic, Gordana, Palma, Marzia, Mellstedt, Hakan, Chen, Puran, Ljunggren, Hans-Gustaf, Hansson, Lotta, Sallberg Chen, Margaret, Buggert, Marcus, Ingelman-Sundberg, Hanna M., Osterborg, Anders
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2023
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482612/ https://www.ncbi.nlm.nih.gov/pubmed/37692865 http://dx.doi.org/10.14740/jh1140

Ejemplares similares

Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination
por: Blixt, Lisa, et al.
Publicado: (2022)

Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXID
por: Chen, Puran, et al.
Publicado: (2023)

Persistence of salivary antibody responses after COVID-19 vaccination is associated with oral microbiome variation in both healthy and people living with HIV
por: Ghorbani, Mahin, et al.
Publicado: (2023)

T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial
por: Blixt, Lisa, et al.
Publicado: (2022)

Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients
por: Blixt, Lisa, et al.
Publicado: (2021)

Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial
por: Bergman, Peter, et al.
Publicado: (2021)

Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals
por: Healy, Katie, et al.
Publicado: (2022)

P609: EFFECT OF LONG-TERM ZANUBRUTINIB TREATMENT ON T-CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: A STUDY CONDUCTED IN PARALLEL WITH THE BGB-3111-304 AND 305 TRIALS.
por: Andersson, Maria, et al.
Publicado: (2023)

SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Show Markedly Reduced Cross-reactivities Against Omicron Variants
por: Lindahl, Hannes, et al.
Publicado: (2023)

Phase I–II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints
por: Winqvist, Maria, et al.
Publicado: (2016)

NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals
por: Cuapio, Angelica, et al.
Publicado: (2022)

Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination
por: Gao, Yu, et al.
Publicado: (2022)

T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers
por: Palma, Marzia, et al.
Publicado: (2017)

Temporary cessation of ibrutinib results in reduced grade 3‐4 infections and durable remissions—Interim analysis of an on‐off‐repeat Phase 1b/2 study in patients with chronic lymphocytic leukemia
por: Lundin, Jeanette, et al.
Publicado: (2021)

Autologous T cells expressing the oncogenic transcription factor KLF6-SV1 prevent apoptosis of chronic lymphocytic leukemia cells
por: Kokhaei, Parviz, et al.
Publicado: (2018)

PB1924: INCIDENCE OF CARDIOVASCULAR AND BLEEDING EVENTS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS (CLL) TREATED WITH IBRUTINIB – A RETROSPECTIVE ANALYSIS ON CONSECUTIVE PATIENTS FROM A WELL-DEFINED REGION.
por: Andersson, Maria, et al.
Publicado: (2023)

Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant
por: Gao, Yu, et al.
Publicado: (2022)

A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib
por: Daneshmanesh, Amir Hossein, et al.
Publicado: (2018)

Elevated CD21(low) B Cell Frequency Is a Marker of Poor Immunity to Pfizer-BioNTech BNT162b2 mRNA Vaccine Against SARS-CoV-2 in Patients with Common Variable Immunodeficiency
por: Bergman, Peter, et al.
Publicado: (2022)

Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia
por: Hojjat-Farsangi, Mohammad, et al.
Publicado: (2015)

Zanubrutinib: past, present, and future
por: Tam, Constantine S., et al.
Publicado: (2023)

Neutralizing SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Give Patients with X-Linked Agammaglobulinemia Limited Passive Immunity to the Omicron Variant
por: Lindahl, Hannes, et al.
Publicado: (2022)

Simultaneous development of zanubrutinib in the USA and China
por: Li, Guanqiao, et al.
Publicado: (2020)

Correction: Zanubrutinib: past, present, and future
por: Tam, Constantine S., et al.
Publicado: (2023)

The Tyrosine Kinase Receptor ROR1 Is Constitutively Phosphorylated in Chronic Lymphocytic Leukemia (CLL) Cells
por: Hojjat-Farsangi, Mohammad, et al.
Publicado: (2013)

Preliminary Evaluation of Zanubrutinib-Containing Regimens in DLBCL and the Cerebrospinal Fluid Distribution of Zanubrutinib: A 13-Case Series
por: Zhang, Yan, et al.
Publicado: (2021)

Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion
por: Tam, Constantine S., et al.
Publicado: (2020)

A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib‐resistant ROR1(+) CLL cells
por: Ghaderi, Amineh, et al.
Publicado: (2021)

Efficacy of Zanubrutinib in the Treatment of Bing–Neel Syndrome
por: Wong, Jonathan, et al.
Publicado: (2018)

Zanubrutinib for mantle cell lymphoma, Waldenström’s macroglobulinaemia
Publicado: (2021)

Zanubrutinib in lymphoproliferative disorders: a comprehensive review
por: Muñoz, Javier, et al.
Publicado: (2022)

Do reduced numbers of plasmacytoid dendritic cells contribute to the aggressive clinical course of COVID‐19 in chronic lymphocytic leukaemia?
por: Smith, Carl Inge Edvard, et al.
Publicado: (2022)

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19
por: Sekine, Takuya, et al.
Publicado: (2020)

MAIT cell compartment characteristics are associated with the immune response magnitude to the BNT162b2 mRNA anti-SARS-CoV-2 vaccine
por: Boulouis, Caroline, et al.
Publicado: (2022)

SARS‐CoV‐2‐specific humoral and cellular immunity persists through 9 months irrespective of COVID‐19 severity at hospitalisation
por: Sandberg, John Tyler, et al.
Publicado: (2021)

Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First
por: Deshpande, Anagha, et al.
Publicado: (2022)

Disseminated fungal infection in a patient receiving zanubrutinib
por: Walsh, Madalyn, et al.
Publicado: (2023)

Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia
por: Tam, Constantine S., et al.
Publicado: (2023)

A novel UHPLC‒MS/MS method for quantitative analysis of zanubrutinib in rat plasma: application to an in vivo interaction study between zanubrutinib and triazole antifungal
por: Tang, Peng-fei, et al.
Publicado: (2023)

Clinical considerations for biosimilar antibodies
por: Mellstedt, Håkan
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_k6v2m51dce6cvu4fu1dic960bc